Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors

Video

In Partnership With:

Erika P. Hamilton, MD, highlights initial findings from the ​ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, highlights initial findings from the ​ongoing phase 1b/2 LIO-1 trial (NCT04042116) in advanced metastatic tumors.

​In the phase 1b portion of the study, investigators wanted to determine the recommended dose of lucitanib in combination with nivolumab (Opdivo) in patients with advanced solid tumors.

Encouraging activity​, including complete and partial responses, was demonstrated in 17 patients who received the combination, says Hamilton. ​Additionally, stable disease was reported in 10 patients.

Notably, these data were seen across several tumor types, including those that do not typically respond to immunotherapy​, Hamilton explains. As such, lucitanib/nivolumab is now being further evaluated ​in the phase 2 portion of the trial.

​In the phase 2 setting, patients with gynecologic cancers will start ​on a 6 mg dose of lucitanib once daily. As tolerated, patients will escalate to 8 mg once daily and 10 mg once daily and receive 480 mg of intravenous nivolumab every 28 days, Hamilton concludes.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS